Takeda, Twist partner on biologics discovery

By The Science Advisory Board staff writers

Twist Bioscience and Takeda Pharmaceutical have formed a partnership for access to Twist's proprietary phage display libraries for the discovery of antibodies in Takeda's biologics pipeline.

Under the agreement, Twist Biopharma will license Takeda its "Library of Libraries," a panel of synthetic antibody phage display libraries derived from human genetic sequences. Together, the companies will work to discover, validate, and optimize new antibody candidates for applications in oncology, rare diseases, neuroscience, and gastroenterology. Takeda will pay Twist annual technology licensing fees, as well as milestone payments and royalties for all compounds discovered from using Twist's phage display libraries.

Copyright © 2020 scienceboard.net

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?